Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 5, 2017, Pages 355-366

  Aroda, Vanita R ^a   Bain, Stephen C ^b   Cariou, Bertrand ^c   Piletič, Milivoj ^d   Rose, Ludger ^e   Axelsen, Mads ^f   Rowe, Everton ^g   DeVries, J Hans ^h  

^a MEDSTAR RESEARCH INSTITUTE   (United States)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c L INSTITUT DU THORAX   (France)

^d General and Teaching Hospital Celje   (Slovenia)

^e Diabetes Research Center   (Germany)

^f NOVO NORDISK A S   (Denmark)

^g NOVO NORDISK INC   (United States)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FATTY ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEMAGLUTIDE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE;

ADD ON THERAPY; ADULT; ARTICLE; ASSESSMENT OF HUMANS; BACKACHE; BENIGN NEOPLASM; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES TREATMENT SATISFACTION QUESTIONNAIRE; DIARRHEA; DYSPEPSIA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SHORT FORM 36; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; MIDDLE AGED;

AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; MALE; METFORMIN; MIDDLE AGED;

EID: 85017156861     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30085-2     Document Type: Article

References (30)

1. 1 Inzucchi, SE, Bergenstal, RM, Buse, JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38 (2015), 140–149.
2. 2 Riddle, MC, Rosenstock, J, Gerich, J, The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003), 3080–3086.
3. 3 Wang, C, Mamza, J, Idris, I, Biphasic vs basal bolus insulin regimen in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Med 32 (2015), 585–594.
4. 4 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
5. 5 Meloni, AR, DeYoung, MB, Lowe, C, Parkes, DG, GLP-1 receptor activated insulin secretion from pancreatic beta-cells: mechanism and glucose dependence. Diabetes Obes Metab 15 (2013), 15–27.
6. 6 Madsbad, S, Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 18 (2015), 317–332.
7. 7 Polonsky, WH, Fisher, L, Hessler, D, Bruhn, D, Best, JH, Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab 13 (2011), 144–149.
8. 8 Lau, J, Bloch, P, Schaffer, L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 58 (2015), 7370–7380.
9. 9 Kapitza, C, Nosek, L, Jensen, L, Hartvig, H, Jensen, CB, Flint, A, Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol 55 (2015), 497–504.
10. 10 Marbury, T, Flint, A, Segel, S, Lindegaard, M, Lasseter, K, Pharmacokinetics and tolerability of a single dose of semaglutide, a once-weekly human GLP-1 analogue, in subjects with and without renal impairment. Diabetologia, 57, 2014, S358 (suppl 1).
11. 11 Sorli, C, Harashima, SI, Tsoukas, GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 5 (2017), 251–260.
12. 12 Nauck, MA, Petrie, JR, Sesti, G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care 39 (2016), 231–241.
13. 13 American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care 37 (2014), S14–S80 (suppl 1).
14. 14 American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13 (2007), 1–68 (suppl 1).
15. 15 Seaquist, ER, Anderson, J, Childs, B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36 (2013), 1384–1395.
16. 16 Russell-Jones, D, Vaag, A, Schmitz, O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52 (2009), 2046–2055.
17. 17 Diamant, M, Van Gaal, L, Stranks, S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375 (2010), 2234–2243.
18. 18 Giorgino, F, Benroubi, M, Sun, JH, Zimmermann, AG, Pechtner, V, Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 38 (2015), 2241–2249.
19. 19 Umpierrez, G, Tofe Povedano, S, Perez Manghi, F, Shurzinske, L, Pechtner, V, Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 37 (2014), 2168–2176.
20. 20 Russell-Jones, D, Cuddihy, RM, Hanefeld, M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 35 (2012), 252–258.
21. 21 Garber, A, Henry, R, Ratner, R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009), 473–481.
22. 22 Nauck, MA, Stewart, MW, Perkins, C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia 59 (2016), 266–274.
23. 23 Weissman, PN, Carr, MC, Ye, J, et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia 57 (2014), 2475–2484.
24. 24 Kahn, SE, Haffner, SM, Heise, MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006), 2427–2443.
25. 25 Diamant, M, Van Gaal, L, Guerci, B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol 2 (2014), 464–473.
26. 26 Marre, M, Shaw, J, Brandle, M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 26 (2009), 268–278.
27. 27 Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
28. 28 Marso, SP, Bain, SC, Consoli, A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
29. 29 Chalmer, T, Almdal, TP, Vilsboll, T, Knop, FK, Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes—focus on pancreatitis and pancreas cancer. Expert Opin Drug Saf 14 (2015), 171–180.
30. 30 Lando, HM, Alattar, M, Dua, AP, Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 18 (2012), 472–477.